Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knox

Showing results (741-750 of 829) with videos related to

Pageof 83
Sort By:
Clinical Genitourinary Cancer|December 3, 2014
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database ConsortiumAndré P Fay, Wanling L Xie, Jae-Lyn Lee, et al.
The Lancet. Oncology|February 16, 2015
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based studyJenny J Ko, Wanling Xie, Nils Kroeger, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor AgonistsMatthew D Hill, Haiquan Fang, H Dalton King, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 16, 2018
Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional studyM K Doherty, Y Leung, J Su, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Clinical Genitourinary Cancer|December 3, 2014
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChristos E Kyriakopoulos, Namita Chittoria, Toni K Choueiri, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Elife|January 4, 2022
Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligandsAaron L Nichols, Zack Blumenfeld, Chengcheng Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
European Urology|August 7, 2013
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapyNils Kroeger, Toni K Choueiri, Jae-Lyn Lee, et al.
Pageof 83

Showing results (741-750 of 829) with videos related to

Sort By:
Pageof 83
Clinical Genitourinary Cancer|December 3, 2014
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database ConsortiumAndré P Fay, Wanling L Xie, Jae-Lyn Lee, et al.
The Lancet. Oncology|February 16, 2015
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based studyJenny J Ko, Wanling Xie, Nils Kroeger, et al.
ACS Medicinal Chemistry Letters|January 21, 2017
Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor AgonistsMatthew D Hill, Haiquan Fang, H Dalton King, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 16, 2018
Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional studyM K Doherty, Y Leung, J Su, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Clinical Genitourinary Cancer|December 3, 2014
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChristos E Kyriakopoulos, Namita Chittoria, Toni K Choueiri, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Elife|January 4, 2022
Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligandsAaron L Nichols, Zack Blumenfeld, Chengcheng Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
European Urology|August 7, 2013
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapyNils Kroeger, Toni K Choueiri, Jae-Lyn Lee, et al.
Pageof 83